TD Cowen has reaffirmed its "Buy" rating for the stock of Dianthus Therapeutics, indicating a positive outlook for the company's financial performance. This decision reflects confidence in Dianthus Therapeutics' business strategy and market position. Investors and analysts will be monitoring the company's developments closely following this endorsement.
Related Articles
Don't miss out on breaking stories and in-depth articles.